A pilot study to evaluate the effect of CT1812 treatment on synaptic density and other biomarkers in Alzheimer's disease.

Journal Information

Full Title: Alzheimers Res Ther

Abbreviation: Alzheimers Res Ther

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Neurology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
4/6
66.7% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Declarations Ethics approval and consent to participateThe informed consent form was required to be signed and dated by the subject and caregiver or study partner before exposure to any study-related procedure, including screening tests for eligibility. The Institutional Review Board (IRB; Yale University IRB, New Haven, CT) reviewed the protocol and the informed consent form. The Investigators were required to conduct all aspects of the study in accordance with all national, state and local laws of applicable Regulatory Authorities. Consent for publicationNot applicable. Competing interestsAOC, SMC, and MEH are current or former employees and shareholders of Cognition Therapeutics, Inc. MG is a consultant to and shareholder in Cognition Therapeutics. APM reports grants for clinical trials from Genentech, Eli Lilly, and Janssen Pharmaceuticals outside the submitted work. RSO, YH, and REC have no relevant competing interests or disclosures to report. CHvD reports consulting fees from Eisai, Roche, Ono, and Cerevel and grants for clinical trials from Biogen, Eli Lilly, Eisai, Roche, Genentech, UCB, and Cerevel outside the submitted work. Competing interests AOC, SMC, and MEH are current or former employees and shareholders of Cognition Therapeutics, Inc. MG is a consultant to and shareholder in Cognition Therapeutics. APM reports grants for clinical trials from Genentech, Eli Lilly, and Janssen Pharmaceuticals outside the submitted work. RSO, YH, and REC have no relevant competing interests or disclosures to report. CHvD reports consulting fees from Eisai, Roche, Ono, and Cerevel and grants for clinical trials from Biogen, Eli Lilly, Eisai, Roche, Genentech, UCB, and Cerevel outside the submitted work."

Evidence found in paper:

"Funding This work was supported by a grant from the National Institute on Aging (Grant # AG057553) and by Cognition Therapeutics, Inc. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health."

Evidence found in paper:

"Trial registration The clinical trial described in this manuscript is registered at clinicaltrials.gov (NCT03493282)."

Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025